Insights into PCSK9-LDLR Regulation and Trafficking via the Differential Functions of MHC-I Proteins HFE and HLA-C

Area of Science:

• Biochemistry
• Immunology
• Molecular Biology

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets the low-density lipoprotein receptor (LDLR) for lysosomal degradation, impacting cholesterol levels.
• The M2 repeat in PCSK9's C-terminal domain is crucial for its function and may interact with unknown proteins.
• Recent studies link PCSK9's M2 repeat to MHC-class-I proteins, suggesting a role in immunity and identifying HLA-like proteins as potential interaction partners.

Purpose of the Study:

• To investigate the roles of MHC-class-I-like proteins, specifically HFE and HLA-C, in modulating PCSK9's extracellular function.
• To elucidate how HFE and HLA-C interactions affect the PCSK9-LDLR pathway and lysosomal degradation.

Main Methods:

• Comparative analysis of HFE and HLA-C interactions with PCSK9.
• Assessment of the impact of these interactions on the intracellular sorting of the PCSK9-LDLR complex.
• Evaluation of PCSK9's activity on LDLR in the presence of HFE and HLA-C.

Main Results:

• The M2 domain of PCSK9 is confirmed to regulate the lysosomal trafficking of the PCSK9-LDLR complex.
• HFE acts as a novel target of PCSK9, inhibiting its activity on LDLR.
• HLA-C enhances the function of PCSK9 in regulating LDLR levels.

Conclusions:

• PCSK9's function in cholesterol homeostasis can be modulated by its interactions with MHC-class-I-like proteins.
• HFE and HLA-C represent key regulators of PCSK9 activity, offering potential avenues for therapeutic intervention.
• This study reveals a novel link between PCSK9, iron homeostasis (via HFE), and immune regulation (via HLA-C).